(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 October 2018 (18.10.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/191479 A1

(51) International Patent Classification:
C07K 16/24 (2006.01) *A61K 39/00* (2006.01)
C07K 14/715 (2006.01)

(21) International Application Number:
PCT/US2018/027271

(22) International Filing Date:
12 April 2018 (12.04.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/484,864	12 April 2017 (12.04.2017)	US
62/553,477	01 September 2017 (01.09.2017)	US
62/553,575	01 September 2017 (01.09.2017)	US

(71) Applicants: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). **MEDIMMUNE LLC** [US/US]; One Medlmmune Way, Gaithersburg, MD 20878 (US).

(72) Inventors: **PARNES, Jane, R.**; 5832 Midddle Crest Drive, Agoura Hills, CA 91301 (US). **GRIFFITHS, Janet**; C/o Medlmmune LLc, One Medlmmune Way, Gaithersburg, MD 20878 (US).

(74) Agent: **NEVILLE, Katherine, L.** et al.; Marshall, Gerstein & Borun Llp, 233s. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: TREATMENT OF ASTHMA WITH ANTI-TSLP ANTIBODY

(57) Abstract: The present disclosure, relates, in general, to methods of treating asthma, including severe asthma and eosinophilic asthma, using an antibody specific for thymic stromal lymphopoietin (TSLP).

WO 2018/191479 A1